Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186628
Status:
COMPLETED
Last Update Posted:
2017-11-28
First Post:
2005-09-14
Brief Title:
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
An Open-label Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLIARG Nonmyeloablative Allogeneic Stem Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease cGvHD
Detailed Description:
To test if prophylactic anti-B-cell therapy weekly rituximab given within 60 to 90 days after allogeneic transplantation will decrease allogeneic donor B-cell immunity and possibly the incidence of chronic graft-vs-host disease cGvHD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 96160 | OTHER | None | None |
| BMT172 | OTHER | None | None |
| SPO | OTHER | None | None |
| P01CA049605 | NIH | Leukemia Lymphoma Society | httpsreporternihgovquickSearchP01CA049605 |